Drugs Made In America Acquisition Corp. (DMAAR) Cash from Investing Activities (2025)

Drugs Made In America Acquisition (DMAAR) has reported Cash from Investing Activities for 1 consecutive years, with -$231.2 million the latest figure, recorded in Q1 2025.

• For the quarter ending Q1 2025, Cash from Investing Activities changed N/A year-over-year to -$231.2 million; the trailing twelve-month figure through Dec 2025 stood at -$231.2 million (changed N/A YoY), and the FY2025 full-year result was -$231.2 million, changed N/A from the prior year.
• Cash from Investing Activities held at -$231.2 million in Q1 2025 per DMAAR's latest filing.
• Across five years, Cash from Investing Activities topped out at -$231.2 million in Q1 2025 and bottomed at -$231.2 million in Q1 2025.